@article{f605aa420c964e6fa56acb00aad43fe2,
title = "Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression",
abstract = "The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a rate-limiting enzyme in the mevalonate biochemical pathway and HMG-CoA reductase inhibitors (statins) show toxicity for certain tumors, including acute myeloid leukemia (AML). This toxicity has been attributed to statin inhibition of Ras isoprenylation in tumors like AML where oncogenic ras mutations and/or overexpression are common. We show that mevastatin kills certain AML cell lines and is more toxic to a majority of primary AML cell samples than to myeloid cells in bone marrow (BM) samples from normal donors, and that mevastatin can produce more than additive kill with standard chemotherapeutics. Mevastatin reduces Ras membrane localization, but statin sensitivity in primary AML cells is not consistently associated with ras mutations nor with Ras overexpression, suggesting that another mevalonate pathway by-product(s) is the statin target in at least some AMLs.",
keywords = "Chemosensitizing, Isoprenylation, Mevalonate pathway, Ras, Statin",
author = "Stirewalt, {D. L.} and Appelbaum, {F. R.} and Willman, {C. L.} and Zager, {R. A.} and Banker, {D. E.}",
note = "Funding Information: The authors thank John J. Cooper and Ali C.M. Johnson for excellent technical assistance, and Jerald P. Radich and Henry Y. Li for critical reading of the manuscript. Supported by a Leukemia and Lymphoma Society Translational Research Award (DEB), NIH grants K12-CA76930 (DS), UO1-CA32102 supporting the Southwest Oncology Group (CLW), CA18029 (FRA), and DK38432 and DK54200 (RAZ). D.L. Stirewalt provided the concept, design, collected and analyzed the data, contributed to the revision and gave final approval. F.R. Appelbaum contributed to the design of the study, provided critical input to the revision and gave final approval. C.L. Willman contributed to the concept, design, providing study materials and gave final approval. R.A. Zager contributed to the study design, revision of the manuscript and gave final approval. D.E. Banker contributed to the concept, design, collection and analysis of data, drafted the paper, obtained funding, assisted with the revision, and gave final approval. ",
year = "2003",
month = feb,
day = "1",
doi = "10.1016/S0145-2126(02)00085-1",
language = "English (US)",
volume = "27",
pages = "133--145",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",
}